Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or future fundraising through debt or equity during the call. The company plans to pursue acquisitions in the current financial year using available cash and possibly some stock. Nikhil Nanda mentioned acquiring facilities and growing inorganically but did not specify raising additional funds through debt or equity. The company has improved its operational efficiency and credit period management, indicating focus on internal resource optimization. No announcements on fresh capital raising or fundraising plans were discussed in the Q4 and FY24 earning

Any current/future capex/capital investment/strategic investment?

No major new capex planned except for specific new moulds for customers, which constitute about 5% to 8% of the overall capex for production lines. Existing production capacity is around 30-35% utilization, targeted to ramp up to 70-80% in the next two years without significant new capex. Some capex is required for new product categories beyond oral care, primarily for packaging lines due to varying packaging needs (pouches, bottles, pumps). The company is actively looking at acquisitions (not mergers) and is confident of undertaking a substantial acquisition in the current financial year usin

Future growth expectations in sales/revenue/volumes?

JHS Svendgaard expects a 30% to 40% increase in revenue for FY25 compared to FY23-24. Growth to be driven by both organic expansion (new customers like Unilever, Amway, Reliance, Zydus) and inorganic acquisitions in broader personal care segments. Capacity utilization targeted to increase from current 30-35% to 70-80% over the next two years without major new capex except for customer-specific moulds. Increased sales volumes anticipated especially as Reliance's general trade oral care business ramps up. Export sales, which dropped during COVID to 1-2% of sales, are recovering with improved ter

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects consistent quarter-on-quarter growth in revenue and profitability over the coming years driven by both organic and inorganic means. FY25 revenue is projected to increase by 30%-40% over FY24. EBITDA margins are expected to improve to healthy mid-teen double digits driven by operational efficiencies, price revisions, and optimized raw material costs. Increased sales volumes are anticipated to bring economies of scale, aiding margin expansion. The company has a firm order book of approximately INR 110 crores for the current financial year with expectations to improve

Current/ Expected Orderbook/ Pending Orders?

The current firm order book for JHS Svendgaard Laboratories Limited stands at approximately INR 110 crores for the financial year 2024-25. The company expects to start executing these orders from Q1 of the current financial year. Management expressed confidence in improving this order book size in the coming months. There is a clear focus on ramping up capacity utilization from the current 30-35% to about 70-80% over the next two years, which would support higher order execution without major new capex. New customers like Reliance, Amway, and Unilever have been added, contributing to t

JHS Sven.Lab.Q4 FY24Personal Products

JHS Sven.Lab. Q4 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹7.99Market Cap: ₹70 CrSector: Personal Products

Management growth scorecard

Revenue

Category 2

Margin

Category 1

Fundraise

N/A

Order

Yes

Capex

Yes

3 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

JHS Svendgaard expects a 30% to 40% increase in revenue for FY25 compared to FY23-24.
Growth to be driven by both organic expansion (new customers like Unilever, Amway, Reliance, Zydus) and inorganic acquisitions in broader personal care segments.
Capacity utilization targeted to increase from current 30-35% to 70-80% over the next two years without major new capex except for customer-specific moulds.
Increased sales volumes anticipated especially as Reliance's general trade oral care business ramps up.
Export sales, which dropped during COVID to 1-2% of sales, are recovering with improved terms and margins.
Management confident about consistent quarter-on-quarter growth in sales, revenue, and profitability in coming years.
Emphasis on maintaining customer diversification with none exceeding 25% of revenue, reducing dependency risks.

Margin guidance

Category 1

The company expects consistent quarter-on-quarter growth in revenue and profitability over the coming years driven by both organic and inorganic means.
FY25 revenue is projected to increase by 30%-40% over FY24.
EBITDA margins are expected to improve to healthy mid-teen double digits driven by operational efficiencies, price revisions, and optimized raw material costs.
Increased sales volumes are anticipated to bring economies of scale, aiding margin expansion.
The company has a firm order book of approximately INR 110 crores for the current financial year with expectations to improve further.
Efforts to add new clients, increase capacity utilization from 30%-35% to around 70%-80% in the next two years will support growth.
Acquisition plans in the personal care segment aim to supplement growth and profitability.
Profitability is targeted to show noticeable improvement starting from Q1 of the current financial year.

See what JHS Sven.Lab. management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no explicit mention of any current or future fundraising through debt or equity during the call.
The company plans to pursue acquisitions in the current financial year using available cash and possibly some stock.
Nikhil Nanda mentioned acquiring facilities and growing inorganically but did not specify raising additional funds through debt or equity.
The company has improved its operational efficiency and credit period management, indicating focus on internal resource optimization.
No announcements on fresh capital raising or fundraising plans were discussed in the Q4 and FY24 earnings conference call.

Order book

Yes

The current firm order book for JHS Svendgaard Laboratories Limited stands at approximately INR 110 crores for the financial year 2024-25.
The company expects to start executing these orders from Q1 of the current financial year.
Management expressed confidence in improving this order book size in the coming months.
There is a clear focus on ramping up capacity utilization from the current 30-35% to about 70-80% over the next two years, which would support higher order execution without major new capex.
New customers like Reliance, Amway, and Unilever have been added, contributing to the order book expansion.
The company is actively pursuing acquisitions to strengthen growth and order inflows further.

See what JHS Sven.Lab. management said on order book — free account, 30 seconds.

Capex plans

Yes

No major new capex planned except for specific new moulds for customers, which constitute about 5% to 8% of the overall capex for production lines.
Existing production capacity is around 30-35% utilization, targeted to ramp up to 70-80% in the next two years without significant new capex.
Some capex is required for new product categories beyond oral care, primarily for packaging lines due to varying packaging needs (pouches, bottles, pumps).
The company is actively looking at acquisitions (not mergers) and is confident of undertaking a substantial acquisition in the current financial year using existing cash and possibly stock.
No new merger plans currently after the Vedic merger did not materialize, with focus shifted to acquisitions instead.

Track JHS Sven.Lab. — get its next earnings analysis in your feed

How does JHS Sven.Lab. rank vs peers in Personal Products?

Pro feature

ThisJHS Sven.Lab.

Rev 2Mar 1

See where JHS Sven.Lab. sits in Personal ProductsSee which companies these are, and every other name in the sector.Open rankings

How does JHS Sven.Lab. rank in Personal Products?

Compare JHS Sven.Lab. against every Personal Products company (Q4 FY24) on revenue, margins and earnings-call signals.

View Personal Products leaderboard →

What JHS Sven.Lab.'s management said in earlier quarters

Others in Personal Products this season

Aakaar Medical (Q2 FY27)
Revenue from operations in H1 FY27: INR 43.72 Cr, up 72.6% YoY from INR 25.32 Cr in H1 FY26 (Page 12, 11, 4) . Key investor presentation takeaways from Aakaar M
Recode Studios Ltd (Q4 FY26)
The company plans to sustain marketing spends at about 20% of revenue to support growth and brand visibility, implying continued focus on operating profits…
Godrej Consumer Products Ltd (Q2 FY27)
Consolidated net sales for Q2 FY2027: ₹4,396 crore, up 19% year-on-year; constant currency growth 15% (Page 8) . Key investor presentation takeaways from Godrej
Colgate-Palmolive (India) Ltd (Q2 FY27)
1,692 crore, up 12.2% year-on-year from Rs. Key results statement takeaways from Colgate-Palmolive (India) Ltd's Q2 FY27 results statement — and how it ranks ag

Compare:vs Godrej Consumer Products Ltd vs Dabur India Ltd vs Cupid Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →